Feasibility and safety of extended‐release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background and aims: HIV‐infected people with substance use disorders are least likely to benefit from advances in HIV treatment. Integration of extended‐release naltrexone (XR‐NTX) into HIV clinics may increase engagement in the HIV care continuum by decreasing substance use. We aimed to compare (1) XR‐NTX treatment initiation, (2) retention and (3) safety of XR‐NTX versus treatment as usual (TAU) for treating opioid use disorder (OUD) and/or alcohol use disorder (AUD) in HIV clinics. Design: Non‐blinded randomized trial of XR‐NTX versus pharmacotherapy TAU. Setting: HIV primary care clinics in Vancouver, BC, Canada and Chicago, IL, USA. Participants: Fifty‐one HIV‐infected patients seeking treatment for OUD (n = 16), AUD (n = 27) or both OUD and AUD (n = 8). Measurements: Primary outcomes were XR‐NTX initiation (receipt of first injection within 4 weeks of randomization) and retention at 16 weeks. Secondary outcomes generated point estimates for change in substance use, HIV viral suppression [HIV RNA polymerase chain reaction (pcr) < 200 copies/ml] and safety. Findings: Two‐thirds (68%) of participants assigned to XR‐NTX initiated treatment, and 88% of these were retained on XR‐NTX at 16 weeks. In comparison, 96% of TAU participants initiated treatment, but only 50% were retained on medication at 16 weeks. Mean days of opioid use in past 30 days decreased from 17.3 to 4.1 for TAU and from 20.3 to 7.7 for XR‐NTX. Mean heavy drinking days decreased from 15.6 to 5.7 for TAU and 12.5 to 2.8 for XR‐NTX. Among those with OUD, HIV suppression improved from 67 to 80% for XR‐NTX and 58 to 75% for TAU. XR‐NTX was well tolerated, with no precipitated withdrawals and one serious injection‐site reaction. Conclusions: Extended‐release naltrexone (XR‐NTX) is feasible and safe for treatment of opioid use disorder and alcohol use disorder in HIV clinics. Treatment initiation appears to be lower and retention greater for XR‐NTX compared with treatment as usual (clinicaltrials.gov NCT01908062).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555
Azar, M. M., Springer, S. A., Meyer, J. P., & Altice, F. L. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.06.014 · Cited by 394
Extended-release naltrexone to prevent opioid relapse in criminal justice offenders
Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., Wilson, D., McDonald, R., Rotrosen, J., Gourevitch, M. N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505409 · Cited by 315
Cited by
Witkiewitz, K., & Vowles, K. E. (2018) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13594 · Cited by 248
“Importantly, AUD diagnosis predicted the significantly higher risk of opioid overdose, accidents, and injuries, as compared to those without an AUD diagnosis (Landsman-Blumberg et al., 2017).”
Parcesepe, A. M., Lancaster, K., Edelman, E. J., DeBoni, R., Ross, J., Atwoli, L., Tlali, M., Althoff, K., Tine, J., Duda, S. N., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237772 · Cited by 24
“Medications, for example, are an important component of treatment for opioid use disorder and alcohol use disorder and have been successfully implemented in U.S.-based HIV clinics [32, 49, 50].”
Contribution of behavioral health factors to non-AIDS-related comorbidities: an updated review
Chichetto, N. E., Polanka, B. M., So-Armah, K. A., Sung, M., Stewart, J. C., Koethe, J. R., Edelman, E. J., Tindle, H. A., & Freiberg, M. S. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00498-y · Cited by 17
Metadata
- Authors
- Korthuis, P. T., Lum, P. J., Vergara‐Rodriguez, P., Ahamad, K., Wood, E., Kunkel, L. E., Oden, N. L., Lindblad, R., Sorensen, J. L., Arenas, V., Ha, D., Mandler, R. N., McCarty, D., & for the CTN‐0055 CHOICES Investigators
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2017-02-08
- Volume
- 112
- Issue
- 6
- Pages
- 1036-1044
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2567850197
- Cited by
- 61
- References
- 5
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.